Rhode Island Child Clinical Trials Collaborative

孩之宝妇幼医院罗德岛儿童临床试验协作组(RI-CCTC) 医院和布朗大学，是ECHO ISPCTN的理想临床中心。我们将在成功的基础上再接再厉 在最初的获奖期间，我们是顶级登记地点，开发了一种新的新生儿阿片类药物网络 戒毒试验方案，并通过我们的委员会工作向网络提供领导。我们州的 人口包括许多未得到充分服务的少数族裔和移民儿童，他们的婴儿比率很高。 死亡率、哮喘、肥胖症、早产儿、精神健康问题和特殊保健需求。这种高风险 人群以前没有被纳入许多临床研究，因此直接和 间接来自国际扶轮-CCTC的工作。罗德岛是以人口为基础的临床研究的独特组织： 它有一家大型产科医院(占该州所有分娩的80%)，一家儿童医院(占所有儿科医院的90%)。 (在该州)和一个卫生部门，以及一个积极参与的社区。这些因素允许 在临床试验中有效地招募、保留和跟踪研究参与者，使RI-CCTC 有可能产生强烈的影响。我们利用了我们丰富的合作网络，与许多现有的 研究、教育和公共卫生项目，以及与国家研究网络的联系。这些 合作伙伴与我们一样致力于儿童健康和儿童健康研究。布朗大学学院 公共卫生和阿尔伯特医学院最近收到了一大笔捐款，创建了哈森菲尔德儿童健康中心 创新研究所(HCHII)，专注于了解产前、围产期和出生后的因素 导致儿童哮喘、肥胖症和自闭症。国际扶轮-CCTC将利用HCHII的资源创建 一个更广泛和更强大的研究网络，为国际扶轮的儿童提供服务。调查人员在 公共卫生和医学院在环境暴露研究方面拥有相当多的专业知识 他们对孩子们的影响。联系人Pi，Thomas Chun医学博士，公共卫生硕士，拥有丰富的多中心经验 网络及其领导力，通过他在ECHO ISPCTN和儿科急诊室的经验 CARE应用研究网络。共同派修道院院长拉帕塔克同样是ISPCTN和NIH的领导人 资助的新生儿研究网络。高级学院发展主管兼联席教授PiPhyllis Dennery医学博士 为她的基础/翻译研究提供了一致的NIH资金，参与了许多培训赠款和 多中心临床试验，并荣获导师奖。这个团队将确保国际扶轮继续取得成功- CCTC在实现ECHO计划的目标和使命方面发挥了重要作用。我们的具体目标是：1)继续提供 在我们现有的基础上，为未得到充分服务的患者登记参加ECHO ISPCTN研究提供新的机会 我们的学术研究中心和机构之间的合作；2)继续提供领导 ECHO ISPCTN和ECHO计划，通过开发新的临床试验和在网络委员会服务； 3)制定和扩大教育和指导临床医生成为独立调查人员的计划。

The Rhode Island Child Clinical Trials Collaborative (RI-CCTC) at Hasbro Children's Hospital, Women & Infants Hospital and Brown University, is an ideal clinical center for the ECHO ISPCTN. We will build on our successes in the initial award period, in which we were a top enrolling site, developed a new network neonatal opioid withdrawal trial protocol, and provided leadership to the network through our committee work. Our state's demographic includes many underserved, minority and immigrant children, who have high rates of infant mortality, asthma, obesity, prematurity, mental health problems and special health care needs. This high risk population has not been previously included in many clinical studies, and thus is benefitting both directly and indirectly from the RI-CCTC's work. Rhode Island is uniquely organized for population-based clinical research: it has one major obstetric hospital (80% of all deliveries in the state), one children's hospital (90% of all pediatric admissions in the state) and one health department, as well as an engaged community. These factors allow for effective enrollment, retention and follow-up of study participants in clinical trials, giving the RI-CCTC the potential to make a strong impact. We have leveraged our rich network of collaborations with many existing research, education and public health programs, as well as affiliations with national research networks. These partners share our commitment to children's health and child health research. The Brown University School of Public Health and the Alpert Medical School, recently received a large gift to create the Hassenfeld Child Health Innovation Institute (HCHII), which is focused on understanding the prenatal, perinatal and postnatal factors that lead to childhood asthma, obesity and autism. The RI-CCTC will leverage the resources of the HCHII to create a much broader and more powerful research network to serve children in the state of RI. Investigators in the Schools of Public Health and Medicine have considerable expertise in the study of environmental exposures and their impact on children. The contact PI, Thomas Chun MD, MPH, has extensive experience with multi-center networks and their leadership, through his experience with the ECHO ISPCTN and the Pediatric Emergency Care Applied Research Network. Co-PI Abbot Laptook similarly is a leader in both the ISPCTN and the NIH funded Neonatal Research Network. Senior Faculty Development Leader and co-PI Phyllis Dennery MD, has had consistent NIH funding for her basic/translational research, has participated in many training grants and multicenter clinical trials, and has won mentoring awards. This team will ensure the continued success of the RI- CCTC in fulfilling the goals and mission of the ECHO Program. Our Specific Aims are to: 1) Continue to provide new opportunities for underserved patient enrollment in ECHO ISPCTN studies by building on our current collaborations between our academic research centers and institutions; 2) Continue to provide leadership to the ECHO ISPCTN and ECHO Program by developing new clinical trials and serving on network committees; 3) Develop and expand programs to educate and mentor clinicians to become independent investigators.